IDNK: A Potential Drug Target Or Biomarker for Cancer (G414328)
IDNK: A Potential Drug Target Or Biomarker for Cancer
IDNK (Integrated DNANK gene) is a gene located on chromosome 16 that has been identified as a potential drug target or biomarker for various diseases, including cancer. The IDNK gene is involved in the immune response and has been shown to play a role in regulating cell death and apoptosis, which are important processes that are often disrupted in cancer cells.
Research has shown that IDNK is expressed in a wide range of tissues and cells, including tissues from cancer-prone organs such as the colon, lung, and breast. It is also highly expressed in human placenta, which is a critical organ that supports the growth and development of fetuses. This suggests that IDNK may be an important biomarker for cancer, as it may be present in the placenta, which is often the site of cancer recurrence.
IDNK has also been shown to play a role in cell death and apoptosis, which are processes that are often disrupted in cancer cells. In fact, studies have shown that IDNK is often overexpressed in cancer cells, which may contribute to their ability to evade the immune system and continue to grow and multiply.
Another study has shown that IDNK is expressed in the brain and that it is involved in the regulation of neurodegenerative diseases. This suggests that IDNK may be an important target for drugs that are being developed to treat these conditions.
IDNK has also been shown to play a role in the regulation of inflammation. Studies have shown that IDNK is involved in the production of pro-inflammatory cytokines, which can contribute to inflammation and tissue damage. This suggests that IDNK may be an important target for drugs that are being developed to treat inflammatory diseases.
In conclusion, IDNK is a gene that has been shown to play a role in the immune response, cell death and apoptosis, and inflammation. Its potential as a drug target or biomarker makes it an attractive target for researchers to investigate further. Further studies are needed to fully understand the role of IDNK in cancer and other diseases, and to identify potential drugs that can target it effectively.
Protein Name: IDNK Gluconokinase
More Common Targets
IDO1 | IDO2 | IDS | IDSP1 | IDUA | IER2 | IER3 | IER3-AS1 | IER3IP1 | IER5 | IER5L | IER5L-AS1 | IFFO1 | IFFO2 | IFI16 | IFI27 | IFI27L1 | IFI27L2 | IFI30 | IFI35 | IFI44 | IFI44L | IFI6 | IFIH1 | IFIT1 | IFIT1B | IFIT2 | IFIT3 | IFIT5 | IFITM1 | IFITM10 | IFITM2 | IFITM3 | IFITM3P2 | IFITM3P7 | IFITM4P | IFITM5 | IFITM8P | IFITM9P | IFNA1 | IFNA10 | IFNA12P | IFNA13 | IFNA14 | IFNA16 | IFNA17 | IFNA2 | IFNA21 | IFNA22P | IFNA4 | IFNA5 | IFNA6 | IFNA7 | IFNA8 | IFNAR1 | IFNAR2 | IFNB1 | IFNE | IFNG | IFNG-AS1 | IFNGR1 | IFNGR2 | IFNK | IFNL1 | IFNL2 | IFNL3 | IFNL4 | IFNLR1 | IFNW1 | IFNWP15 | IFNWP19 | IFRD1 | IFRD2 | IFT122 | IFT122P3 | IFT140 | IFT172 | IFT20 | IFT22 | IFT27 | IFT43 | IFT46 | IFT52 | IFT57 | IFT74 | IFT80 | IFT81 | IFT88 | IFTAP | IGBP1 | IGBP1P1 | IGDCC3 | IGDCC4 | IgE Receptors | IGF1 | IGF1R | IGF2 | IGF2-AS | IGF2BP1 | IGF2BP2